Результаты исследования препарата Хондроксид при остеоартрозе коленных суставов
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Список литературы
1. Рациональная фармакотерапия ревматических заболеваний: руководство для практикующих врачей. Т. III. Гл. 12. М.: Литтерра, 2003.
2. Алексеева Л. И. Современные подходы к лечению остеоартроза. РМЖ. 2003; 11 (4): 201–5.
3. Osteoarthritis. Clinical and Experimental aspects. Ed. JE.Register, JP.Pelletier, Y.Pelletier. Henrotin. Springer, 1999.
4. Martel-Pelletier J, Lajeunesse D, Pelletier JP. Etiopathogenesis of osteoarthritis. In Arthritis and Allied Conditions: A Textbook of Rheumatology. Edited by: Koopman WJ, Moreland LW, Baltimore: Lippincott, William Wikins, 2005; 2199–96.
5. Felson DT, Laurence RC et al. Osteoarthritis: new insight. Part II: Treatment approach. Ann Intern Med 2000; 133: 726–37.
6. Laurence D, Massicotte F, Pelletier JP, Martel-Pelletier J. Subchondral bone sclerosis in osteoarthritis: not just an innocept bystander. Modem Rheumatol 2003; 13: 7–14.
7. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report or a Task Force of Stending Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
8. Zhang W, Moscovitz RW, Nuki G et al. OARSI recommendations for the menegement of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16 (2): 137–62.
9. Cappell MS, Schein JR. Diagnosis and treatment of nonsteroidal anti-inflametory drug-associated upper gastrointestinal toxicity. Gastrointerol Clin N Am 2000; 29: 97–124.
10. Tenenbaum О. The epidemiology of nonsteroidal anti-inflametory drugs. Can J Gastrointerol 1999; 13: 119–22.
11. Насонова В.А., Алексеева Л.И., Архангельская Г.С. и др. Итоги многоцентрового клинического исследования препарата Структум в России. Тер. арх. 2001; 11: 84–7.
12. Насонов Е.Л., Алексеева Л.И. Хондроитин сульфат (Структум) при лечении остеоартроза: патогенетическое обоснование и клиническая эффективность. Тер. арх. 2001; 11: 87–9.
13. Baici A, Bradamante P. Interaction between human leukocyte elastase and chondroitin sulfate. Chem Biol Interaction 1984; 51: 1–11.
14. Jomphe C, Gabriac M, Hale TM et al. Chondroitin Sulfate Inhibits the Nuclear Translocation of Nuclear Factor-κB in Interleucin-1b-Stimulated Chondrocytes. Jornal complitation 2007 Nordic Pharmacological Sosiety & Clinical Pharmacology & Toxicology, 102: 59–65.
15. Hashimoto S, Takabasbi K, Amiel В et al. Chondrocyte apoptosis and nutric oxide production in expirementally induced osteoarthritis. Arthr Rheum 1998; 41: 1266–74.
16. Conrozier T. Death of articular chondrocytes. Mechanisms and protection. Pres Med 1998; 21: 1859–61.
17. McAlindon TE, La Valley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. LAMA 2000; 283: 1469–75.
18. Leeb BF, Schweizer M, Montag K, Smolen J. A meta-analisis of chondroitin sulphate in treatment of osteoarthritis. J Rheumatol 2000; 27: 205–11.
19. Bana G, Jamard B, Verrouil E, Mazieres B. Chondroitin sulfate in the management of hip and knee OA: an overview. Adv Pharmacol 2006; 53: 507–22.
20. Michel BA, Stucki G, Frey D et al. Chondroitin 4 and 6 sulfate in osteoarthritis of the knee: A randomized, controlled trial. Arthritis Rheum 2005; 52 (3): 779–86.
21. Uebelhart D, Knols R, de Bruin ED, Verbruggen G. Chondroitin sulfate as a structure-modifying agent. Adv Pharmacol 2006; 53: 475–88.
22. Youyg Ho Lee, Jin-Hyun Woo et al. Effect of glucosamin or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int, Published on line: 21 June 2009.
23. Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: SYDMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthrit Cartil 1998; 6 (Suppl. A): 37–8.
24. Jordan KMM, Arden NK. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Terapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
25. Hathcock JN, Shao A. Risk assessment for Glucosamine and chondroitin sulfate. Regulat Toxicol Pharmacol 2007; 47: 78–83.
2. Алексеева Л. И. Современные подходы к лечению остеоартроза. РМЖ. 2003; 11 (4): 201–5.
3. Osteoarthritis. Clinical and Experimental aspects. Ed. JE.Register, JP.Pelletier, Y.Pelletier. Henrotin. Springer, 1999.
4. Martel-Pelletier J, Lajeunesse D, Pelletier JP. Etiopathogenesis of osteoarthritis. In Arthritis and Allied Conditions: A Textbook of Rheumatology. Edited by: Koopman WJ, Moreland LW, Baltimore: Lippincott, William Wikins, 2005; 2199–96.
5. Felson DT, Laurence RC et al. Osteoarthritis: new insight. Part II: Treatment approach. Ann Intern Med 2000; 133: 726–37.
6. Laurence D, Massicotte F, Pelletier JP, Martel-Pelletier J. Subchondral bone sclerosis in osteoarthritis: not just an innocept bystander. Modem Rheumatol 2003; 13: 7–14.
7. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report or a Task Force of Stending Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
8. Zhang W, Moscovitz RW, Nuki G et al. OARSI recommendations for the menegement of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16 (2): 137–62.
9. Cappell MS, Schein JR. Diagnosis and treatment of nonsteroidal anti-inflametory drug-associated upper gastrointestinal toxicity. Gastrointerol Clin N Am 2000; 29: 97–124.
10. Tenenbaum О. The epidemiology of nonsteroidal anti-inflametory drugs. Can J Gastrointerol 1999; 13: 119–22.
11. Насонова В.А., Алексеева Л.И., Архангельская Г.С. и др. Итоги многоцентрового клинического исследования препарата Структум в России. Тер. арх. 2001; 11: 84–7.
12. Насонов Е.Л., Алексеева Л.И. Хондроитин сульфат (Структум) при лечении остеоартроза: патогенетическое обоснование и клиническая эффективность. Тер. арх. 2001; 11: 87–9.
13. Baici A, Bradamante P. Interaction between human leukocyte elastase and chondroitin sulfate. Chem Biol Interaction 1984; 51: 1–11.
14. Jomphe C, Gabriac M, Hale TM et al. Chondroitin Sulfate Inhibits the Nuclear Translocation of Nuclear Factor-κB in Interleucin-1b-Stimulated Chondrocytes. Jornal complitation 2007 Nordic Pharmacological Sosiety & Clinical Pharmacology & Toxicology, 102: 59–65.
15. Hashimoto S, Takabasbi K, Amiel В et al. Chondrocyte apoptosis and nutric oxide production in expirementally induced osteoarthritis. Arthr Rheum 1998; 41: 1266–74.
16. Conrozier T. Death of articular chondrocytes. Mechanisms and protection. Pres Med 1998; 21: 1859–61.
17. McAlindon TE, La Valley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. LAMA 2000; 283: 1469–75.
18. Leeb BF, Schweizer M, Montag K, Smolen J. A meta-analisis of chondroitin sulphate in treatment of osteoarthritis. J Rheumatol 2000; 27: 205–11.
19. Bana G, Jamard B, Verrouil E, Mazieres B. Chondroitin sulfate in the management of hip and knee OA: an overview. Adv Pharmacol 2006; 53: 507–22.
20. Michel BA, Stucki G, Frey D et al. Chondroitin 4 and 6 sulfate in osteoarthritis of the knee: A randomized, controlled trial. Arthritis Rheum 2005; 52 (3): 779–86.
21. Uebelhart D, Knols R, de Bruin ED, Verbruggen G. Chondroitin sulfate as a structure-modifying agent. Adv Pharmacol 2006; 53: 475–88.
22. Youyg Ho Lee, Jin-Hyun Woo et al. Effect of glucosamin or chondroitin sulfate on the osteoarthritis progression: a meta-analysis. Rheumatol Int, Published on line: 21 June 2009.
23. Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: SYDMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthrit Cartil 1998; 6 (Suppl. A): 37–8.
24. Jordan KMM, Arden NK. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Terapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62: 1145–55.
25. Hathcock JN, Shao A. Risk assessment for Glucosamine and chondroitin sulfate. Regulat Toxicol Pharmacol 2007; 47: 78–83.
Авторы
Е.П.Шарапова, Л.И.Алексеева
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.